eye launch
sale well ahead our/consensu
forecast led us out-performance medicar us commerci
busi beat expect ou strong beat oper
margin slightli ahead opex leverag partial off-set lower gm
one-tim obsol charg limit launch way full launch
expect prior ada june sale guidanc rais midpoint
manag bless street estim surprisingli
like impact somewhat upgrad programs/pati potenti wait
overal take account competit dynam guidanc manag
note good sign respect attrit price dynam ahead big
launch quarter
note us sale outpac estim
medicare/commerci out-performance gross margin impact
sever item primarili obsolete-inventori charg acceler
transit new touch screen receiv warranti expens go
look ahead owe improv receiv reach mileston
total sale
offer upgrad program wherebi patient purchas two
transmitt receiv one transmitt free avail result
revenu deferr get captur within
upon launch trial expect initi new low-
cost transmitt target launch
guidanc thought manag see consensu estim reason
compani assum impact revenu deferr come
upgrad program potenti paus patient await
guidanc assum chang revenu per patient assum sensor price
flat patient util trend similar new sensor
note factor price headwind guidanc
seen impact us date opex still expect grow
ex-invest non-intens insulin market expans new icgm
design potenti quicker approv timelin open product
iter possibl previous rule
estim sale estim rise
beat estim includ strong intern growth build
medicar forecast sale growth modest type
first verili sale built-in upsid potenti rais estim price target
rise
medic devic
compani focus design
develop continu glucos
monitor cgm system diabet
patient product includ
platinum mobil cgm
analyst certif import disclosur see disclosur
cgm penetr type diabet reach
next year
us growth slow assum
competitor impact off-set increment medicar sale continu
solid intern growth reimburs broaden
modest penetr type patient non-medicar begin
type contribut sale beyond modest current
higher gross margin new cost initi
forecast solid sale growth
under-penetrated patient popul robust pipelin
next sever
year despit new competit near-term driver
gener sensor augment pump partnership well
verili devic unit healthcar studi collabor
open larger opportun
launch sensor augment pump pump partner
competitor launch lead greater market share loss
price target driven discount cash flow assum weight averag cost capit
termin growth rate base estim ebitda price target impli ev/sal multipl
risk includ competit slowdown revenu due macroeconom pressur clinic trial fda risk
